Navrogen, Inc., a Philadelphia, PA-based biotechnology company, raised $3.2M in convertible note financing.
The round was led by Ben Franklin Technology Partners of South Eastern Pennsylvania and a number of private investors.
The company wil use the funds to to support its operations, Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities.
Led by Nicholas Nicolaides, Ph.D., Chief Executive Officer, and Luigi Grasso, Ph.D., Chief Scientific Officer, Navrogen is a biotechnology company focused on the discovery of tumor produced HIO-factors that are associated with cancer prognosis and therapeutic response of immune-mediated anti-cancer therapies. Its mission is to develop diagnostic assays that can identify patients whose tumors produce HIO-factors to advise physicians on therapeutic options as well as develop agents that can overcome the immuno-suppressive effects of a specific HIO-factor.